Here are the 424B prospectus supplements from Revelation Biosciences, Inc. (REVB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow REVB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full REVB filings page.
Revelation Biosciences, Inc. is registering for resale up to 4,272,500 shares of common stock issuable upon exercise of Class J Common Stock Warrants held by selling stockholders. The company is not selling shares in this offering and will not receive proceeds from any resale.
The Class J warrants have a $3.44 exercise price and become exercisable after stockholder approval for five years. If all 4,272,500 warrants are exercised for cash, Revelation could receive up to approximately $14,697,400, which it plans to use for preclinical and clinical development, working capital and general corporate purposes.
This resale follows a private warrant inducement in which two investors exercised 2,136,251 Class I warrants at $3.44 per share, providing gross proceeds of $7,348,699 and receiving the Class J warrants. Shares outstanding were 2,623,118 as of January 26, 2026, and would be 6,895,618 assuming full warrant exercise and resale.